Discovery for Precision Care
Using artificial intelligence-based tools and blood test analysis, this program aims to optimize current treatment strategies using a precision therapy approach to the management of metastatic disease focused on CRCLM and HCC.
We are studying the molecular mechanisms of primary liver cancers and metastatic disease. Our lab has developed in vitro and in vivo models. Our unique access to patient samples allows to validate our findings and further our translational research.
Pathobiology of Fatty Liver Disease
Investigating the biochemical and genetic changes associated with the pathogenesis and etiology of non-alcoholic fatty liver disease and non-alcoholic steaotohepatitis. Part of the MUHC Research Institute Fatty Liver Integrative Research Team initiative.
Our Liver Disease Biobank is an established liver and colon disease biobank.